Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate

Kunlin Wang; Changquan Calvin Sun

doi:10.1016/j.ijpharm.2021.120239

Direct compression tablet formulation of celecoxib enabled with a pharmaceutical solvate

Int J Pharm. 2021 Mar 1:596:120239. doi: 10.1016/j.ijpharm.2021.120239. Epub 2021 Jan 21.

Authors

Kunlin Wang¹, Changquan Calvin Sun²

Affiliations

¹ Pharmaceutical Materials Science and Engineering Laboratory, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 9-127B Weaver-Densford Hall, 308 Harvard Street S.E., Minneapolis, MN 55455, United States.
² Pharmaceutical Materials Science and Engineering Laboratory, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 9-127B Weaver-Densford Hall, 308 Harvard Street S.E., Minneapolis, MN 55455, United States. Electronic address: sunx0053@umn.edu.

PMID: 33484921
DOI: 10.1016/j.ijpharm.2021.120239

Abstract

Celecoxib, an anti-inflammatory drug for pain and arthritis, is currently only available in capsule form. To reduce the onset time for a faster action and to lower the manufacturing cost, the tablet dosage form is more preferred. However, the commercial celecoxib (Form III) is not suitable for direct compression (DC) tablet manufacture due to poor flow, low bulk density, and tablet lamination. In this work, we overcome these challenges using a pharmaceutically acceptable dimethyl sulfoxide (DMSO) solvate of celecoxib. Aided with the DMSO solvate, an acceptable DC tablet formulation was successfully developed to manufacture tablets containing 200 mg celecoxib, with satisfactory manufacturability, disintegration, and in vitro dissolution performance.

Keywords: Celecoxib; Crystal engineering; Direct compression; Formulation development; Solvate.

MeSH terms

Celecoxib
Chemistry, Pharmaceutical*
Pressure
Tablets

Substances

Tablets
Celecoxib